Ubrogepant

Category: pharmacological

Aliases: Ubrelvy

Pharmacological Mechanism

Small-molecule CGRP receptor antagonist for acute migraine. Same trigeminovascular CLR/RAMP1 receptor target as rimegepant; shorter half-life. CYP3A4 substrate — strong inhibitors contraindicated.

Half-Life (t½)

PO: 6h

Dosing Guidelines

• PO: Typical 100 mg (Range: 50–100 mg)

Target Organ Systems

• nervous
• digestive

Pathways It Modulates

• CGRP axis (inhibitor) — CGRP receptor

Chemical Identifiers

• PubChem CID: 68748835
• Formula: C29H26F3N5O3
• Molecular weight: 449.42 g/mol
• InChIKey: DDOOFTLHJSMHLN-ZQHRPCGSSA-N
• SMILES: C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6

References

• PMID 38266060